Recombinant factor VIIa
Open-knowledge reference entry
Recombinant factor VIIa (rfVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. It is administered via an injection into a vein. It is used to treat bleeding episodes in people who have acquired hemophilia, among other indications.
The most common side effects with Novoseven include venous thromboembolic events (problems caused by blood clots in the veins), rash, pruritus (itching), urticaria (hives), fever and reduced effectiveness of treatment. The most common side effects with Cevenfacta include injection site discomfort and hematoma (a collection of blood under the skin) as well as injection-related reactions, an increase in body temperature, dizziness and headache.
Novoseven was authorized for medical use in the European Union in February 1996, and in the United States in March 1999.
Medical uses
Novoseven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgical interventions or invasive procedures in people with acquired hemophilia.
Novoseven RT is indicated for the treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII deficiency, and Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets and for the treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia.
Sevenfact [coagulation factor VIIa (recombinant)-jncw] is approved for use in the United States and is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents twelve years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies).
As of 2012, recombinant factor VIIa is not supported by the evidence for treating most cases of major bleeding.
The public source identifies “Recombinant factor VIIa” as open-knowledge reference entry. This brief keeps that definition visible, then builds a research path around Recombinant, factor and VIIa.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Recombinant factor VIIa”, the useful work is to connect “open-knowledge reference entry” to the records capable of establishing context and consequence.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Aug 23, 2026. The linked authority identifier is Q5940878. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1996, 1999 and 2012.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Recombinant factor VIIa”, its source revision and the description used here.
- Expand the search: follow Recombinant factor VIIa primary sources, Recombinant factor VIIa archive and Recombinant research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Recombinant factor VIIa”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Recombinant factor VIIa” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.